Torrent Pharmaceuticals Ltd (TORNTPHARM) Q1 FY27 Results Analysis: EBITDA Margin Expands 130 bps, Revenue Surges 17%
Torrent Pharmaceuticals Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 4,921.00 Cr (+54.80% YoY) and PAT growth of +3.30% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 30, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 4,921.00 Cr (+54.80% YoY) |
| PAT (Q1) | Rs. 566.00 Cr (+3.30% YoY) |
| EBITDA margin | 33.80% (+130 bps YoY) |
| EPS (Q1) | Rs. 14.87 (-8.15% YoY) |
| Market cap | Rs. 185,319.02 Cr |
| CMP | Rs. 4,872.10 |
Quarter Snapshot
Base business revenue grew 17% YoY, ahead of the 10-15% guidance, and consolidated EBITDA margin expanded 130 bps YoY to 33.8%. The JB Pharma acquisition delivered a 35.3% EBITDA margin, well above the guided 28-29% range, indicating faster-than-expected synergy realization. However, PAT growth was muted at 3.3% due to elevated finance costs and depreciation, and Germany business continued to decline 24% YoY due to supply disruption.
Key Investment Insights
Key Positives
- Base business revenue grew 17% YoY to Rs.3,720 Cr, ahead of the 10-15% guidance band.
- Consolidated EBITDA margin expanded 130 bps YoY to 33.8%, the highest in reported periods.
- JB Business EBITDA margin improved to 35.3% from 28.8% in Q1 FY26, beating the guided 28-29% range.
- India base business grew 19% YoY, outpacing IPM growth of ~12%, indicating market share gains.
- Net worth more than doubled to Rs.17,848 Cr due to the JB Pharma amalgamation, improving debt/equity from 1.76x to 0.82x.
Risk Factors
- PAT to owners grew only 3.3% YoY despite revenue growth of 54.8%, as finance costs (Rs.305 Cr, +444.6% YoY) and D&A (Rs.593 Cr, +195.0% YoY) from the JB acquisition absorbed incremental revenue.
- Germany business (Others) declined 24% YoY to Rs.112 Cr due to persistent supply disruption, continuing for third consecutive quarter.
- Other income remained negative at Rs.(12) Cr due to net foreign exchange losses, adding to margin pressure.
- Finance costs increased 444.6% YoY and 29.2% QoQ, reflecting the full quarter's interest on acquisition debt.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.